Clinical trials: Rifampin
Leprosy
Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)
This study will evaluate a combination of bedaquiline and rifampicin as post exposure prophylaxis (PEP) for leprosy in Comoros. It will be a follow-up to the PEOPLE trial on PEP with rifampicin, which is ending in 2022.
- Trial name
- BE-PEOPLE P2 (NCT05406479)
- Testing
- BE-PEP (Bedaquiline), SDR-PEP, BE-PEP (Rifampicine)
- Where
- Comoros
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
HIV-1-infection
Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD
Tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) is being used more widely across the world to treat HIV. This is an observational study (a type of study in which participants are observed and certain outcomes are…
- Trial name
- NCT04050449
- Where
- 14 sites in Haiti, Kenya and 4 more
- Volunteers
- 1,339 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Hydrocephalus
Bactiseal Catheter Safety Registry in China
Research Purpose: This study aimed to continue to evaluate safety information from subjects implanted with a catheter (trade name: Bactiseal) produced by Codman \& Shurtleff, Inc. of the United States.
- Trial name
- NCT04496414
- Testing
- Bactiseal Catheter
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Integra LifeSciences Corporation
HIV Infection, Tuberculosis
Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis
The purpose of this study is to determine the best time to begin anti-HIV treatment in individuals who have HIV and tuberculosis (TB).
- Trial name
- STRIDE (NCT00108862)
- Testing
- Strategy: Immediate ART, Strategy: Deferred ART
- Where
- 26 sites in United States, Botswana and 11 more
- Volunteers
- 809 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Rifampicin-resistant Tuberculosis
French National Cohort of Patients With Rifampicin-Resistant Tuberculosis
A major obstacle in the fight against multidrug-resistant tuberculosis is its treatment. In 2021, only 60% of patients with MDR/RR tuberculosis who received treatment globally were successfully cured, while 12% succumbed to the…
- Trial name
- CONTRol-TB (NCT06565806)
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mild Spinal Tuberculosis
Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis
To evaluate the non-inferiority in efficacy between the rifapentine- and moxifloxacin-containing short-course regimens (with rifampicin replaced by rifapentine and ethambutol replaced by moxifloxacin, while isoniazid and…
- Trial name
- NCT06917495
- Testing
- Rifampin, Isoniazid, Rifapentine (RPT)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shandong University
Pediatric HIV Infection, Tuberculosis Infection
Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin
Tuberculosis (TB) is the leading cause of death among children with HIV, yet insufficient data are available on the pharmacokinetics of newer HIV/TB cotreatment strategies in children.
- Trial name
- NCT05069688
- Testing
- rifampicin
- Where
- Nigeria
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Tuberculosis
Comparative Effectiveness/Implementation of TB Case Finding in Rural South Africa
The purpose of this study is to compare three strategies for finding TB cases in a rural Sub-Saharan African setting: 1) Screening all attendees of primary care clinics for TB; 2) Conducting household contact investigations of…
- Trial name
- Kharitode TB (NCT02808507)
- Testing
- Active TB case finding
- Where
- 2 sites in South Africa
- Volunteers
- 4,852 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Prosthesis-related Infections, Staphylococcal Infections
Rifampin Combination Therapy Versus Monotherapy in Early Staphylococcal Infections After Total Hip and Knee Arthroplasty
The number of patients requiring joint replacement is increasing due to its success in restoring function and pain relief, and the growing population of the elderly.
- Trial name
- NCT00423982
- Testing
- Rifampin-combination therapy, Monotherapy
- Where
- 8 sites in Norway
- Volunteers
- 100 people
- Sponsor
- Oslo University Hospital
Meningitis, Tuberculous, Pharmacokinetics
Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study
Tuberculous meningitis (TBM) is the most lethal form of tuberculosis infection, and is diagnosed in approximately 5-10% of TB patients.
- Conditions
- Meningitis, Tuberculous, Pharmacokinetics, Pharmacodynamics, Tolerability
- Trial name
- NCT01158755
- Testing
- Moxifloxacin
- Where
- Indonesia
- Volunteers
- 60 people
- Sponsor
- Universitas Padjadjaran
Postoperative Infection Rates
Powder Topical Rifampicin on Reducing Infections After Neural Tube Defect Surgery in Infants
The correct timing and technique of neural tube defect (NTD) repairs significantly decreases the morbidity and mortality of NTD cases. However, infections related to the surgery are still common.
- Trial name
- NCT03198819
- Testing
- Local Rifampisin and İnrtravenous cefotaxime
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Yuzuncu Yil University
HIV Infection
REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
People with HIV have a high chance of becoming infected with TB, especially when they live in areas where TB infection is common. It can be difficult to diagnose TB in people who need to start HIV treatment right away.
- Trial name
- REMEMBER (NCT01380080)
- Testing
- Atripla (r), Efavirenz, Truvada
- Where
- 18 sites in Brazil, Haiti and 8 more
- Volunteers
- 851 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Seropositivity, Tuberculosis
Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
A multicenter, randomized, stratified, open-label, phase IV trial among HIV-positive persons (PLHIV) on antiretroviral therapy (ART), or HIV-negative household contacts of patients with rifampicin-sensitive pulmonary tuberculosis…
- Conditions
- HIV Seropositivity, Tuberculosis, Household Contact
- Trial name
- 1 to 3 (NCT05118490)
- Testing
- Daily rifapentine and isoniazid for 4 weeks, Weekly rifapentine and isoniazid for 12 weeks
- Where
- 4 sites in India, Indonesia and 2 more
- Volunteers
- 1,000 people
- Sponsor
- The Aurum Institute NPC
Tuberculosis, HIV
Rifampin and Nevirapine Interactions in Young Children
Nevirapine is the preferred nonnucleoside reverse transcriptase inhibitor (NNRTI) for treatment of HIV in children younger than 3 years old who have tuberculosis (TB) coinfection.
- Trial name
- NCT01699633
- Where
- Ghana
- Volunteers
- 58 people
- Sponsor
- The Miriam Hospital
Tuberculosis, HIV
Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment
This will be a Phase IIIb Clinical Trial, an international multicenter, randomized, three-arm, non-comparative trial of efficacy, safety, and tolerability of the dual therapy regimen dolutegravir plus lamivudine either twice…
- Trial name
- DOVETAIL (NCT06497465)
- Testing
- Dolutegravir 50mg Tab, Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO], Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)
- Where
- 5 sites in Brazil
- Volunteers
- 150 people
- Sponsor
- Johns Hopkins University
Pulmonary TB
Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease
RIFAstrat is a Phase 3, double-blind, placebo-controlled, non-inferiority trial to compare the 6-month standard treatment for DS-TB with a 4-month optimised- rifampicin based regimen provided to individuals with limited disease…
- Trial name
- RIFAstrat (NCT07118696)
- Testing
- Extra 600mg of Rifampicin
- Volunteers
- 1,000 people
- Sponsor
- Hamilton Health Sciences Corporation
Cystic Fibrosis
Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis
The purpose of this study is to determine antimycobacterial drug pharmacokinetics (PK) and pharmacodynamics (PD) in patients with cystic fibrosis (CF) to improve treatment of nontuberculous mycobacterial (NTM) lung disease.
- Trial name
- NCT02372383
- Testing
- Ethambutol, Rifampin, Azithromycin
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Tuberculosis, Meningeal
High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study
Tuberculous meningitis (TBM) is the most severe form of tuberculosis infection with high mortality. Current treatment regimens are not based on clinical trials.
- Trial name
- ReDEFINe (NCT02169882)
- Testing
- Rifampicin, Other TB drugs, Adjuvant dexamethasone
- Where
- Indonesia
- Volunteers
- 60 people
- Sponsor
- Universitas Padjadjaran
Tuberculosis, Pulmonary
Impact of Malnutrition on Pharmacokinetic of Rifampicin, Isoniazid, Pyrazinamide and Ethambutol in TB-HIV Co-infected Children (TB-Speed TB-PK)
TB-Speed TB-PK is a cross-sectional PK study of anti-TB treatment nested in the TB-Speed HIV and TB-Speed SAM studies aiming at assessing the impact of malnutrition on PK of rifampicin, isoniazid, pyrazinamide, and ethambutol in…
- Trial name
- NCT04972903
- Where
- 4 sites in Uganda, Zambia
- Volunteers
- 85 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
HIV Infections, Tuberculosis
Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis
The purpose of this study is to determine if a relationship exists between the level of antituberculosis drugs (isoniazid, rifampin, ethambutol, and pyrazinamide) in the blood and the outcome of HIV-positive patients with…
- Trial name
- NCT00000950
- Testing
- Ethambutol hydrochloride, Isoniazid, Pyrazinamide
- Where
- 13 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)